Parkwalk Opportunities EIS Fund and the University of Oxford Innovation Fund IV have invested in Oxford Endovascular to support the development of Oxiflow, a novel flow-diverting device for treating intracranial aneurysms.

Target Information

Oxford Endovascular has developed a groundbreaking medical device known as Oxiflow, which represents the next generation of flow-diverting technologies. This innovative device is designed to redirect blood flow away from intracranial aneurysms that are at risk of rupture, thereby enhancing patient safety and treatment outcomes. Constructed as a metallic mesh tube and manufactured from Nitinol, a specialized Nickel Titanium alloy, Oxiflow's patented design allows for greater accuracy and safety during deployment compared to existing solutions. Its adaptability to conform to various blood vessel shapes minimizes the likelihood of complications, effectively expanding the pool of patients eligible for treatment.

Industry Overview

The medical device industry in the United Kingdom is robust and continually evolving, characterized by significant investment in innovative technologies. The sector is bolstered by strong research and development capabilities, particularly in relation to advanced materials and minimally invasive procedures. The UK's favorable regulatory environment and established healthcare infrastructure also support the growth of medical device companies.

At the heart of this industry is a drive toward improving patient outcomes and enhancing procedural safety. Recent years have seen a surge in demand for advanced vascular treatments,